What are the causes of hypertension in nephrotic syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Causes of Hypertension in Nephrotic Syndrome

Hypertension in nephrotic syndrome results primarily from sodium retention and volume expansion due to intrinsic kidney defects in sodium excretion, compounded by medication effects (particularly corticosteroids and calcineurin inhibitors), disease severity, and underlying glomerular pathology.

Primary Pathophysiologic Mechanisms

Sodium Retention and Volume Expansion

The fundamental mechanism is excessive sodium retention occurring independently of renin-angiotensin-aldosterone system (RAAS) activation 1. This represents an intrinsic defect where factors present in nephrotic urine directly activate sodium transporters in the kidney, leading to:

  • Volume expansion
  • Increased intravascular pressure
  • Fluid shifts contributing to both edema and hypertension

This mechanism explains why hypertension in nephrotic syndrome can be particularly difficult to control and why dietary sodium restriction to <2.0 g/day (<90 mmol/day) is essential 2.

Disease-Related Factors

Steroid resistance and frequent relapses are major risk factors for developing hypertension 3:

  • Steroid-resistant nephrotic syndrome: 70% develop hypertension (adjusted HR 1.47)
  • Steroid-dependent disease: 67% develop hypertension (adjusted HR 1.81)
  • Frequently-relapsing disease: 63% develop hypertension (adjusted HR 1.64)
  • Infrequently-relapsing disease: 42% develop hypertension

The overall incidence is striking—53% of children with nephrotic syndrome develop hypertension during follow-up (incidence rate 8.2 per 100 person-years) 3.

Secondary Contributing Factors

Medication-Induced Hypertension

  • Corticosteroids: Cause acute and episodic blood pressure elevations through sodium retention and metabolic effects 4
  • Calcineurin inhibitors (CNIs): Associated with sustained hypertension through vasoconstriction and nephrotoxicity 4

Chronic Kidney Disease Progression

As nephrotic syndrome progresses, additional mechanisms emerge 4:

  • Renal fibrosis
  • Decreased glomerular filtration rate
  • Structural kidney damage
  • Glomerular hyperfiltration in remaining nephrons (can lead to focal segmental glomerulosclerosis-like lesions) 5

Obesity and Metabolic Factors

Higher body mass index Z-score is an independent risk factor for hypertension development in steroid-sensitive patients 3. This compounds the cardiovascular risk profile already elevated in nephrotic syndrome patients.

Rare but Important Causes

Renovascular Disease

Though uncommon, renal artery stenosis can present with severe hypertension and massive proteinuria mimicking primary nephrotic syndrome 6. In these cases:

  • High renin state drives both hypertension and proteinuria
  • ACE inhibitors can dramatically reduce proteinuria by controlling the renin-angiotensin axis
  • Nephrectomy of the affected kidney may be curative 5

Clinical pitfall: Always consider secondary causes of hypertension, particularly in newborns or patients with severe, refractory hypertension.

Clinical Implications for Blood Pressure Monitoring

Beyond office measurements, nephrotic syndrome patients have high prevalence of 4:

  • Ambulatory hypertension
  • Abnormal blood pressure circadian rhythm
  • Increased blood pressure variability
  • Masked hypertension

Close blood pressure surveillance is justified given the 53% incidence and association with cardiovascular complications including left ventricular hypertrophy, arterial stiffness, and endothelial dysfunction 3, 4.

Management Framework Based on KDIGO 2021

The KDIGO guidelines emphasize a stepwise approach 2:

  1. Lifestyle modifications (synergistic with pharmacotherapy):

    • Sodium restriction <2.0 g/day
    • Weight normalization
    • Regular exercise
    • Smoking cessation
  2. Pharmacologic therapy:

    • ACE inhibitors or ARBs for blood pressure control and proteinuria reduction
    • Potassium-wasting diuretics to enable RAS blockade
    • Mineralocorticoid receptor antagonists for refractory cases
  3. Intensified sodium restriction for patients failing to achieve proteinuria reduction on maximal medical therapy

Critical caveat: Monitor labs frequently when using ACE inhibitors or ARBs, and counsel patients to hold these medications plus diuretics during volume depletion or sick days 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.